Laurus Labs generated Rs 2,206 crore in second-quarter revenue alongside a net profit of Rs 441 crore, reflecting significant operational scaling. For the first half of FY27, overall revenue rose 31% to Rs 4,233 crore while EBITDA margin reached 33.2%. The firm continues to reinvest heavily, holding capital expenditure at 20% of revenue to fund network developments. In addition to operational advancements, the company declared an interim dividend of Re 1 per share for its shareholders.
Key points
The company operationalised its first commercial-scale peptide manufacturing facility loc…: The company operationalised its first commercial-scale peptide manufacturing facility located in Vizag with further capacity additions underway.
Sustained capital expenditure at 20% of revenue is dedicated to advancing niche capabilit…: Sustained capital expenditure at 20% of revenue is dedicated to advancing niche capabilities and overall network expansions.
Targeted capital allocations are being directed toward oligonucleotides and peptide-resin…: Targeted capital allocations are being directed toward oligonucleotides and peptide-resin technologies to strengthen the integrated CDMO platform.
Sources checked by our analysis pipeline: 1
The strong quarterly performance was driven by sustained growth in its contract development and manufacturing organisation (CDMO) business and continued momentum in its Affordable Medicines division.
In its exchange filing, Laurus Labs, a research and development-driven pharmaceutical and biotechnology company, reported revenue of Rs 2,206 crore for Q2FY27, compared with Rs 1,653 crore in the corresponding quarter last year.
Net profit surged 126% YoY to Rs 441 crore from Rs 195 crore in Q2FY26, while EBITDA climbed 78% to Rs 762 crore from Rs 429 crore in the year-ago quarter.
The company's EBITDA margin stood at 34.5% during the quarter, while gross margin expanded to 63% from 59.9% in Q2FY26.
Commenting on the performance, Dr Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said the company delivered another record quarter in terms of revenue and profitability, reflecting the strength of its CDMO platform and Affordable Medicines portfolio.
He highlighted the operationalisation of the company's first commercial-scale peptide manufacturing plant in Vizag, adding that significant capacity expansion was already underway to address rising demand for peptide therapeutics. The company…
Novartis is heavily banking on its investigational multiple sclerosis therapy remibrutinib to generate billions in revenue as impending patent expirations threaten major revenue streams. Although the Swiss pharmaceutical firm weathered recent generic competition for its heart drug Entresto, it faces an estimated $18 billion revenue risk when blockbuster treatments Kisqali and Kesimpta lose patent exclusivity around 2032.
India's apex judicial body has stepped in to examine a long-running energy dispute involving deepwater assets in the Krishna-Godavari basin. The litigation centers on government allegations that commercial operators extracted and sold substantial volumes of migrated natural gas without authorization. The final verdict will determine whether the private energy consortium must satisfy massive financial claims stemming from accusations of unjust enrichment and fraud.
Executives at Oracle Cloud Infrastructure are treating the massive New Mexico facility as routine business despite mounting hurdles that have pushed company shares down over 30% this year. The development is designed to support OpenAI, but severe utility delays have pressured its construction debt and triggered a force majeure notice. Because lease terms obligate the tech firm to secure power and cover debt liabilities, the setback poses significant financial exposure.